INTASYL™, Phio’s proprietary RNA interference (RNAi) technology, makes immune cells more effective in killing tumor cells.
The success of several pre-clinical studies has attracted new and industry-experienced leadership to Phio Pharmaceuticals. The new leadership will join forces with the current executive team to move the company forward as it evolves INTASYL™, its proprietary platform, from discovery to development.
INTASYL™ is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL™ drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.
If you share our determination to look beyond established treatments and to achieve outcomes that were once out of reach, join us. You can learn more about joining the Phio team by contacting firstname.lastname@example.org or by visiting us on LinkedIn to see our current employment opportunities. Or, click below to learn more about us and our team.
Get in touch with us.